A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Academic Curriculum Components Bookmark and Share

Academic Curriculum Components

Clinical Cancer Genetics Course
All trainees in City of Hope’s Cancer Genetics Career Development Program (CGCDP) are required to complete this 16-week course. This course provides a comprehensive knowledge base in cancer genetics, including the following:
 
  • Carcinogenesis: cellular, molecular, genetic and environmental etiology
  • Clinical features, pathology, epidemiology and treatment of cancer
  • Hereditary cancer syndromes
  • Cancer risk assessment
  • Cancer genetic counseling skills development
  • Genetic testing: legal, ethical and insurance issues related to genetic testing
  • Role of cancer registries and clinical research trials
 
Curriculum materials are developed as a ten-day, 60-hour CME-accredited intensive course, which is also open to cancer risk counselors in underserved communities.

The course curriculum is updated periodically under the direction of the Advisory Committee to accommodate the rapid developments in cancer genetics knowledge. Faculty and trainees have the opportunity to deliver selected lectures and update course content.
 
Cancer Genetics Working Group
The CME-accredited Clinical Cancer Genetics Working Group is comprised of experts from various disciplines who discuss cases and the best care for each patient. The Working Group convenes weekly to:

Review all Cancer Screening & Prevention Program Network (CSPPN) patient and family case histories Discuss cancer risk assessment, genetic test results interpretation and management strategies Discuss case-related interpersonal and familial psychosocial issues, and candidacy for chemopreventive, epidemiological and behavioral research protocolsThe rich clinical experience, coupled with multidisciplinary case discussion, form the cornerstone of the program's experiential training.
 
Topics in Clinical Cancer Genetics
A weekly lecture series focuses on issues in clinical cancer genetics and cancer genetics research, alternating between didactic lectures and “journal club.” Participants comment on and interpret primary research reports on key topics in molecular cancer genetics, risk assessment, epidemiological and behavioral research, and clinical cancer prevention. They learn how to present findings in summary form and incorporate important research findings into clinical practice and research projects. This lecture series is a primary forum for updates. A list of these topics and attachments to the related articles are also posted on our WebBoard, “The Genetics Link.”

The Genetics Link is City of Hope’s Clinical Cancer Genetics web forum. To expand their practical knowledge in the field of clinical cancer genetics, members of this discussion group exchange ideas and receive valuable feedback from experts and from one another. Membership in The Genetics Link is open by invitation only and to those who have been part of the Clinical Cancer Genetics Technology Transfer Research (CCGTTR) courses and outreach activities.
 
In collaboration with Dr. Stanley Azen, Director of the USC Graduate Programs in Biometry and Epidemiology, a dual-track customized curriculum in cancer epidemiology was initiated with University of Southern California (USC). The curriculum consists of two modules, in which trainees enroll concurrently.
 
All trainees are required to participate in selected topics.

 

 

Academic Curriculum Components

Academic Curriculum Components

Clinical Cancer Genetics Course
All trainees in City of Hope’s Cancer Genetics Career Development Program (CGCDP) are required to complete this 16-week course. This course provides a comprehensive knowledge base in cancer genetics, including the following:
 
  • Carcinogenesis: cellular, molecular, genetic and environmental etiology
  • Clinical features, pathology, epidemiology and treatment of cancer
  • Hereditary cancer syndromes
  • Cancer risk assessment
  • Cancer genetic counseling skills development
  • Genetic testing: legal, ethical and insurance issues related to genetic testing
  • Role of cancer registries and clinical research trials
 
Curriculum materials are developed as a ten-day, 60-hour CME-accredited intensive course, which is also open to cancer risk counselors in underserved communities.

The course curriculum is updated periodically under the direction of the Advisory Committee to accommodate the rapid developments in cancer genetics knowledge. Faculty and trainees have the opportunity to deliver selected lectures and update course content.
 
Cancer Genetics Working Group
The CME-accredited Clinical Cancer Genetics Working Group is comprised of experts from various disciplines who discuss cases and the best care for each patient. The Working Group convenes weekly to:

Review all Cancer Screening & Prevention Program Network (CSPPN) patient and family case histories Discuss cancer risk assessment, genetic test results interpretation and management strategies Discuss case-related interpersonal and familial psychosocial issues, and candidacy for chemopreventive, epidemiological and behavioral research protocolsThe rich clinical experience, coupled with multidisciplinary case discussion, form the cornerstone of the program's experiential training.
 
Topics in Clinical Cancer Genetics
A weekly lecture series focuses on issues in clinical cancer genetics and cancer genetics research, alternating between didactic lectures and “journal club.” Participants comment on and interpret primary research reports on key topics in molecular cancer genetics, risk assessment, epidemiological and behavioral research, and clinical cancer prevention. They learn how to present findings in summary form and incorporate important research findings into clinical practice and research projects. This lecture series is a primary forum for updates. A list of these topics and attachments to the related articles are also posted on our WebBoard, “The Genetics Link.”

The Genetics Link is City of Hope’s Clinical Cancer Genetics web forum. To expand their practical knowledge in the field of clinical cancer genetics, members of this discussion group exchange ideas and receive valuable feedback from experts and from one another. Membership in The Genetics Link is open by invitation only and to those who have been part of the Clinical Cancer Genetics Technology Transfer Research (CCGTTR) courses and outreach activities.
 
In collaboration with Dr. Stanley Azen, Director of the USC Graduate Programs in Biometry and Epidemiology, a dual-track customized curriculum in cancer epidemiology was initiated with University of Southern California (USC). The curriculum consists of two modules, in which trainees enroll concurrently.
 
All trainees are required to participate in selected topics.

 

 
Clinical Cancer Genetics
The City of Hope Division of Clinical Cancer Genetics is committed to being a national leader in the advancement of cancer genetics, screening and prevention, through innovative patient care, research and education.

Contact Us
  • 800-826-HOPE (4673)
  • For more information about the Cancer Screening & Prevention Program, call 626-256-8662, ext. 2.
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
City of Hope Breakthroughs
Get the latest in City of Hope's research, treatment and news you can use on our blog, Breakthroughs.
 
 
NEWS & UPDATES
  • Beyond the pink ribbons, special product fundraisers, and the pastel sea of color that marks October, Breast Cancer Awareness Month offers a reason to celebrate and to reflect. More than 2.8 million breast cancer survivors live in the U.S. They are survivors of the second most-common cancer in women, behind ski...
  • Gliomas, a type of tumor that grows in the brain, are very difficult to treat successfully due to their complex nature. That might not always be the case. First some background: The most aggressive and common type of primary brain tumor in adults is glioblastoma. Although the brain tumor mass can often be remov...
  • Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. The result is rashes and, sometimes, tumors, which can be mistaken for other dermatological conditions. In a smal...
  • Weighing your breast cancer risk? One study suggests a measure to consider is skirt size. A British study suggests that for each increase in skirt size every 10 years after age 25, the five-year risk of developing breast cancer postmenopause increases from one in 61 to one in 51 – a 77 percent increase in risk....
  • Runners prize medals for 5Ks and marathons. Becky Stokes has a medal she cherishes from a very different kind of race: the marathon of treatments necessary to beat her aggressive triple-negative breast cancer. Just a week ago, she completed her last radiation treatment, and danced in the hospital with the staff...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. Darakjian’s s...
  • The environment plays a role in causing cancer – this much we know. But scientists are still trying to understand what that role is, what environmental factors are in play and how precisely those factors are linked to cancer. Now City of Hope researchers have unlocked a clue as to how one carcinogen triggers ca...
  • Jonathan Yamzon, M.D., assistant clinical professor of surgery in the Division of Urology and Urologic Oncology, explains his approach to what’s known as “active surveillance” of men with prostate cancer. Patients need to be educated about their treatment options, he writes. Active surveillanc...
  • For most prostate cancer patients, surgery or radiation therapy is the initial and primary treatment against the disease. But some patients can benefit from chemotherapy and hormone therapy too, especially if there are signs of a relapse or if the cancer has spread beyond the prostate gland. Here, Cy Stein, M.D...
  • Cancer research has yielded scientific breakthroughs that offer patients more options, more hope for survival and a higher quality of life than ever before. The 14.5 million cancer patients living in the United States are living proof that cancer research saves lives. Now, in addition to the clinic, hospital an...
  • Advances in cancer treatment, built on discoveries made in the laboratory then brought to the bedside, have phenomenally changed the reality of living with a cancer diagnosis. More than any other time in history, people diagnosed with cancer are more likely to survive and to enjoy a high quality of life. Howeve...
  • While health care reform has led to an increase in the number of people signing up for health insurance, many people remain uninsured or are not taking full advantage of the health benefits they now have. Still others are finding that, although their premiums are affordable, they aren’t able to see the do...
  • Kidney cancer rates and thyroid cancer rates in adults have continued to rise year after year. Now a new study has found that incidence rates for these cancers are also increasing in children — particularly in African-American children. The study, published online this month in Pediatrics, examined childhood ca...
  • Thyroid cancer has become one of the fastest-growing cancers in the United States for both men and women. The chance of being diagnosed with the cancer has nearly doubled since 1990. This year an estimated 63,000 people will be diagnosed with thyroid cancer in the United States and nearly 1,900 people will die ...
  • Older teenagers and young adults traditionally face worse outcomes than younger children when diagnosed with brain cancer and other central nervous system tumors. A first-of-its-kind study shows why. A team of researchers from the departments of Population Sciences and Pathology at City of Hope recently examine...